[Effects of sodium iodide symporter co-expression on proliferation and cytotoxic activity of chimeric antigen receptor T cells
chimeric antigen receptor T cells
co-expression
killing activity
proliferation in vitro
sodium iodide symporter
Journal
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
ISSN: 1673-4254
Titre abrégé: Nan Fang Yi Ke Da Xue Xue Bao
Pays: China
ID NLM: 101266132
Informations de publication
Date de publication:
20 Jul 2022
20 Jul 2022
Historique:
entrez:
23
7
2022
pubmed:
24
7
2022
medline:
27
7
2022
Statut:
ppublish
Résumé
To investigate the effects of co-expression of sodium iodide symporter (NIS) reporter gene on the proliferation and cytotoxic activity of chimeric antigen receptor (CAR)-T cells T cells expressing CD19 CAR (CAR-T cells), NIS reporter gene (NIS-T cells), and both (NIS-CAR-T cells) were prepared by lentiviral infection. The transfection rates of NIS and CAR were determined by flow cytometry, and the cell proliferation rate was assessed using CCK-8 assay at 24, 48 and 72 h of routine cell culture. The T cells were co-cultured with Nalm6 tumor cells at the effector-target ratios of 1∶2, 1∶1, 2∶1 and 4∶1 for 24, 48 and 72 h, and the cytotoxicity of CAR-T cells to the tumor cells was evaluated using lactate dehydrogenase (LDH) assay. ELISA was used to detect the release of IFN-γ and TNF-β in the co-culture supernatant, and the function of NIS was detected with iodine uptake test. The CAR transfection rate was 91.91% in CAR-T cells and 99.41% in NIS-CAR-T cells; the NIS transfection rate was 47.83% in NIS-T cells and 50.24% in NIS- CAR-T cells. No significant difference in the proliferation rate was observed between CAR-T and NIS-CAR-T cells cultured for 24, 48 or 72 h ( The co-expression of the NIS reporter gene does not affect CAR expression, proliferation or tumor cell-killing ability of CAR-T cells.
Identifiants
pubmed: 35869771
doi: 10.12122/j.issn.1673-4254.2022.07.15
pmc: PMC9308869
doi:
Substances chimiques
Antineoplastic Agents
0
Lymphotoxin-alpha
0
Receptors, Chimeric Antigen
0
Symporters
0
sodium-iodide symporter
4XE5NDT4K1
Iodine
9679TC07X4
Types de publication
Journal Article
Langues
chi
Sous-ensembles de citation
IM
Pagination
1062-1068Références
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Mol Ther. 2017 May 3;25(5):1248-1258
pubmed: 28366766
Clin Cancer Res. 2021 Feb 15;27(4):1058-1068
pubmed: 33087332
Mol Ther. 2020 Oct 7;28(10):2271-2285
pubmed: 32645298
Expert Opin Biol Ther. 2020 Jun;20(6):653-664
pubmed: 32067497
Trends Cancer. 2018 May;4(5):359-373
pubmed: 29709260
Sci Adv. 2019 Jul 03;5(7):eaaw5096
pubmed: 31281894
Mol Ther. 2020 Jan 8;28(1):42-51
pubmed: 31668558
Front Oncol. 2020 Jul 07;10:1000
pubmed: 32733795
J Clin Med. 2019 Feb 07;8(2):
pubmed: 30736426
Front Immunol. 2020 Nov 26;11:603237
pubmed: 33324420
AJNR Am J Neuroradiol. 2008 Feb;29(2):229-34
pubmed: 18024575
Nat Immunol. 2021 Jul;22(7):865-879
pubmed: 34140678
J Clin Oncol. 2020 Nov 10;38(32):3805-3815
pubmed: 33021872
Curr Gene Ther. 2012 Feb 1;12(1):33-47
pubmed: 22263922
Immunol Lett. 2019 Aug;212:53-69
pubmed: 31181279
AJNR Am J Neuroradiol. 2008 Mar;29(3):409-18
pubmed: 18272565
Bone Marrow Transplant. 2019 Oct;54(10):1643-1650
pubmed: 30809033
Curr Mol Pharmacol. 2022;15(3):532-546
pubmed: 34382510
Cancer Res. 2020 Nov 1;80(21):4731-4740
pubmed: 32958548
Nat Rev Drug Discov. 2016 Apr;15(4):235-47
pubmed: 26965203
Cytotherapy. 2016 Nov;18(11):1393-1409
pubmed: 27592405
Methods Enzymol. 2021;651:291-311
pubmed: 33888207
Annu Rev Physiol. 2017 Feb 10;79:261-289
pubmed: 28192058
Oncoimmunology. 2020 May 13;9(1):1757360
pubmed: 32923113
Biomark Res. 2017 Jun 24;5:22
pubmed: 28652918
Adv Exp Med Biol. 2020;1244:215-233
pubmed: 32301017
JCI Insight. 2016 Nov 17;1(19):e90064
pubmed: 27882353
Nat Commun. 2018 Mar 14;9(1):1081
pubmed: 29540684
Methods Mol Biol. 2020;2086:61-67
pubmed: 31707667